{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/glaucoma/management/primary-open-angle-glaucoma-intraocular-hypertension/","result":{"pageContext":{"chapter":{"id":"803a56e6-2082-5ccc-add9-0d7bd9f32f6a","slug":"primary-open-angle-glaucoma-intraocular-hypertension","fullItemName":"Scenario: Primary open angle glaucoma and intraocular hypertension","depth":2,"htmlHeader":"<!-- begin field 5017a158-d8a5-420d-8c18-2fa5aadd35cf --><h2>Scenario: Primary open angle glaucoma and ocular hypertension</h2><!-- end field 5017a158-d8a5-420d-8c18-2fa5aadd35cf -->","summary":"Covers the primary healthcare professional's role in the shared care management of primary open angle glaucoma and ocular hypertension, and some information as to how these conditions are treated in secondary care.","htmlStringContent":"<!-- begin item e595cf88-cfad-4aec-a646-62da75015920 --><!-- begin field 4c3dc82d-ec21-49c1-a118-acbc01596d3b --><p>From age 16 years onwards.</p><!-- end field 4c3dc82d-ec21-49c1-a118-acbc01596d3b --><!-- end item e595cf88-cfad-4aec-a646-62da75015920 -->","topic":{"id":"2f2ce020-977b-56c2-bfe0-79af338099b2","topicId":"3f1d1b43-0970-4917-b518-15a04dfd4397","topicName":"Glaucoma","slug":"glaucoma","lastRevised":"Last revised in November 2020","chapters":[{"id":"b70753e1-40bf-5d64-8042-80499a3a3663","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"99932988-c7ac-5201-8a03-324771c52186","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4665a282-8076-541c-8fdb-d884f514e73a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"90547efd-385b-5418-95dc-840a239bb4b6","slug":"changes","fullItemName":"Changes"},{"id":"744db240-54ad-5b2b-bde1-fbf5f82dd75c","slug":"update","fullItemName":"Update"}]},{"id":"1b9b2a0b-c1eb-5850-81a4-594deb443996","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d96d012a-8a50-5197-a3bc-80be922d4ec3","slug":"goals","fullItemName":"Goals"},{"id":"ab168d63-48cb-5e39-af87-b20be5416a2b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1371aed7-3648-50af-9b62-765d61209340","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e5d9b1dc-20e2-5c90-807b-c86643d03e27","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"634d007b-489f-5899-be8c-e79e2c12d416","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"895cf400-6256-5dd3-9e84-20a916980e46","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"05123836-33c6-55ab-87b4-82c858ac280b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e281b4eb-d1e1-5e3a-ac1e-ba1ce5a60a71","slug":"definition","fullItemName":"Definition"},{"id":"1d1f8e60-4614-5dcc-a66d-9019ca4e6e03","slug":"anatomy-physiology","fullItemName":"Anatomy and physiology"},{"id":"00e7c765-c989-527f-b21f-29ad09409af8","slug":"classification","fullItemName":"Classification"},{"id":"855a9d74-8bb6-54d9-bfc9-5c385ae0f3f4","slug":"causes","fullItemName":"Causes"},{"id":"89456b4f-1b83-5bd6-ba80-018c1171090d","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"37e8081e-c003-5262-a267-bf22817b2d3d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"592dbfb6-31cc-55a6-a38e-b77abbd29565","slug":"prognosis","fullItemName":"Prognosis"},{"id":"f95b1f20-8f4d-5e8f-9e11-426b2a59246a","slug":"complications","fullItemName":"Complications"}]},{"id":"86e2bb04-52a3-5765-8605-aa439e65cf40","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"c3238d06-745f-57aa-b5f9-69dc42896f15","slug":"primary-angle-closure-glaucoma","fullItemName":"Primary angle closure glaucoma"},{"id":"f7c27cd1-50e2-5977-9f46-b1ae6e37f8c6","slug":"ocular-hypertension-primary-open-angle-glaucoma","fullItemName":"Ocular hypertension and primary open angle glaucoma"},{"id":"8f240bf4-5d3c-57ba-a2f7-5e0b82983e5c","slug":"opportunistic-testing-for-glaucoma","fullItemName":"Opportunistic testing for glaucoma"}]},{"id":"c621d247-f521-559a-93ce-c62c3ab5fd2b","fullItemName":"Management","slug":"management","subChapters":[{"id":"1e08cb89-b766-5a2f-9853-4406baa8635c","slug":"acute-angle-closure-angle-closure-glaucoma","fullItemName":"Scenario: Acute angle closure and angle closure glaucoma"},{"id":"803a56e6-2082-5ccc-add9-0d7bd9f32f6a","slug":"primary-open-angle-glaucoma-intraocular-hypertension","fullItemName":"Scenario: Primary open angle glaucoma and intraocular hypertension"}]},{"id":"2d512acb-6e34-566f-8f5f-90eb0d0c8431","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d784c3ec-391a-5275-a286-56b128e61629","slug":"topical-prostaglandin-analogues-prostamides","fullItemName":"Topical prostaglandin analogues and prostamides"},{"id":"7d644d35-69fa-5a6f-8ceb-fab24019dcee","slug":"topical-beta-blockers","fullItemName":"Topical beta-blockers"},{"id":"7a8c1c4a-8a2d-5555-828d-58b50a740f88","slug":"topical-sympathomimetics","fullItemName":"Topical sympathomimetics"},{"id":"9a1dce0a-a42d-5d80-8ded-a8444facf830","slug":"carbonic-anhydrase-inhibitors","fullItemName":"Carbonic anhydrase inhibitors"},{"id":"efeb705d-eba6-581c-93ad-0916f0aed1c4","slug":"topical-miotics","fullItemName":"Topical miotics"}]},{"id":"657fc5fb-6ac1-5cfe-8fde-6a6eaf21e17b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"14521c62-39fa-5ea2-9b3b-ba4a79d55565","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"4d0bdf94-c9fe-564d-bd78-4e6e957019c7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4dec5995-8a6e-599f-a3ec-4401dda0f2fc","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"fbee715b-cedc-51e6-91f9-00319ab7944f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"802ad5b9-1cd1-59e9-8b22-2239d0b31c19","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4211d06e-9a65-51ea-ac4d-d35ca789f223","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"85b73253-be63-5a83-8948-152e3b5a51f7","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c621d247-f521-559a-93ce-c62c3ab5fd2b","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"83b837f4-125f-59b0-b5e0-e267495db9f5","slug":"management-of-primary-open-angle-glaucoma-ocular-hypertension","fullItemName":"Management of primary open angle glaucoma and ocular hypertension","depth":3,"htmlHeader":"<!-- begin field 892be8cc-0b03-4364-b1eb-c55264a3a323 --><h3>How are primary open angle glaucoma and ocular hypertension managed?</h3><!-- end field 892be8cc-0b03-4364-b1eb-c55264a3a323 -->","summary":null,"htmlStringContent":"<!-- begin item 9b708397-d086-492c-9619-00aece721020 --><!-- begin field 6d849341-88a6-45f4-8ecc-b6b01b198851 --><ul><li><strong>The aim of treatment </strong>is to prevent the development of, or the further progression of, glaucoma, and thus to preserve sight as much as possible. </li><li><strong>Management of ocular hypertension (OH), suspected primary open angle glaucoma (POAG), and confirmed POAG are normally under the direction of an ophthalmologist.</strong><ul><li>No treatment is required for some people with mild OH but they require monitoring by an optometrist who may refer to an ophthalmologist for treatment, when appropriate. <ul><li>Criteria for referral are based largely on the person's age, their intraocular pressure (IOP), their central corneal thickness, and if signs of glaucoma develop. </li></ul></li><li>If treatment is recommended by an ophthalmologist, a target IOP is established, and first-line treatment is usually either: <ul><li>A topical <a class=\"topic-reference internal-reference\" href=\"/topics/glaucoma/prescribing-information/topical-prostaglandin-analogues-prostamides/\">prostaglandin analogue or prostamide</a>.</li><li>A topical <a class=\"topic-reference internal-reference\" href=\"/topics/glaucoma/prescribing-information/topical-beta-blockers/\">beta-blocker</a>.</li></ul></li><li>Lifetime monitoring is routine once treatment is commenced.</li><li>If a first-line treatment is unsuccessful, or not tolerated, second-line treatment options that may be considered by the ophthalmologist include:<ul><li>Switching to a drug in the other first-line drug class.</li><li>Combining a topical prostaglandin analogue or prostamide with a topical beta-blocker.</li><li>Switching to, or adding in, a second-line drug treatment, which are: a topical <a class=\"topic-reference internal-reference\" href=\"/topics/glaucoma/prescribing-information/topical-sympathomimetics/\">sympathomimetic</a>, a topical <a class=\"topic-reference internal-reference\" href=\"/topics/glaucoma/prescribing-information/carbonic-anhydrase-inhibitors/\">carbonic anhydrase inhibitor</a>, or a topical <a class=\"topic-reference internal-reference\" href=\"/topics/glaucoma/prescribing-information/topical-miotics/\">miotic</a>.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/glaucoma/management/primary-open-angle-glaucoma-intraocular-hypertension/#laser-surgical-treatment-options\">Laser or surgical</a> procedures — note: in late 2019 NICE recommended that current guidance should be updated to reflect that selective laser trabeculoplasty is an effective <em>first-line</em> treatment for OH and POAG.</li></ul></li></ul></li><li><strong>Primary care practitioners may have a role in management to:</strong><ul><li>Promote the correct use of eye drops and adherence to treatment.</li><li>Continue prescribing medications initiated by a specialist.</li><li>Monitor for <a class=\"topic-reference internal-reference\" href=\"/topics/glaucoma/management/primary-open-angle-glaucoma-intraocular-hypertension/#allergy-to-eye-drops\">allergy</a> and other adverse effects of eye drops. For further information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/glaucoma/prescribing-information/\">Prescribing information</a>.</li><li>Provide <a class=\"topic-reference internal-reference\" href=\"/topics/glaucoma/management/primary-open-angle-glaucoma-intraocular-hypertension/#patient-information-support\">information</a>, including about driving, and signpost to reliable, evidence-based information providers.</li></ul></li></ul><!-- end field 6d849341-88a6-45f4-8ecc-b6b01b198851 --><!-- end item 9b708397-d086-492c-9619-00aece721020 -->","subChapters":[{"id":"17d74fae-45d2-5238-b47e-2d52e1fa9d19","slug":"laser-surgical-treatment-options","fullItemName":"Laser and surgical treatment options","depth":4,"htmlHeader":"<!-- begin field 07a1bb1f-8a75-47b3-80aa-a53c8abfde61 --><h4>What are the laser and surgical treatment options in secondary care?</h4><!-- end field 07a1bb1f-8a75-47b3-80aa-a53c8abfde61 -->","summary":null,"htmlStringContent":"<!-- begin item 51fad5aa-d6b0-4b5f-903c-4b2b2639bfb9 --><!-- begin field 465f6f1c-9b73-49c3-beb9-7c325a0a9fed --><ul><li>A laser or surgical procedure are options to treat primary open angle glaucoma (POAG).</li><li>Laser procedures that may be considered include:<ul><li>Selective laser trabeculoplasty (SLT).<ul><li>SLT involves a low-energy laser being fired at the trabecular meshwork. It is thought to work by selectively targeting melanin pigment that occurs in a proportion of cells in the trabecular meshwork, thus leaving non-pigmented cells unscathed. This increases the drainage capacity of the trabecular meshwork but causes little damage to the structures there. Therefore, if needed, it can be safely repeated.</li><li>Evidence is accumulating to suggest that SLT is often as effective as medical therapy to achieve target intraocular pressures. </li></ul></li><li>Argon laser trabeculoplasty (ALT).<ul><li>This uses a high-energy laser to burn holes in the trabecular meshwork to increase the drainage of aqueous humour. Owing to the thermal damage caused by ALT, repeated treatments are not usually an option. </li></ul></li><li>Micropulse laser trabeculoplasty (MLT).<ul><li>This is a relatively new technique. It uses repeated very short duration pulses of laser to deliver energy to the trabecular meshwork but causes little tissue damage owing to the short duration of each pulse that allows the tissue to cool between pulses. </li></ul></li></ul></li><li>Surgical procedures that may be considered include:<ul><li>Trabeculectomy.<ul><li>In this procedure a small hole is created in the sclera to allow the drainage of aqueous humour from the anterior chamber to a small reservoir (a 'bleb') that is created under the conjunctiva. The bleb is normally hidden by the upper eyelid. The fluid dissipates from the bleb into the blood supply of the conjunctiva.</li></ul></li><li>Insertion of a drainage shunt.<ul><li>In this procedure a small flexible tube (usually made of silicon) is inserted through the sclera into the anterior chamber. This then allows the aqueous humour to drain out into a tiny artificial reservoir attached to the end of the tube under the conjunctiva. The fluid then dissipates from the reservoir into the blood supply of the conjunctival tissues. </li><li>There are various types of shunt, some with pressure valves that regulate the flow of aqueous humour.</li></ul></li></ul></li></ul><!-- end field 465f6f1c-9b73-49c3-beb9-7c325a0a9fed --><!-- end item 51fad5aa-d6b0-4b5f-903c-4b2b2639bfb9 -->","subChapters":[]},{"id":"2418b445-f830-5da8-aa8d-e374a9365d23","slug":"basis-for-recommendation-10c","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 24ada526-36f1-4ad9-abce-210e9886190a --><h4>Basis for recommendation</h4><!-- end field 24ada526-36f1-4ad9-abce-210e9886190a -->","summary":null,"htmlStringContent":"<!-- begin item 10c92530-f2fc-4209-89ed-8df534b69c05 --><!-- begin field 8d0a192f-38a3-4423-92d4-6b87b71fbabf --><p>The recommendations and information on management of ocular hypertension and primary open angle glaucoma are largely based on expert opinion within the Royal College of Ophthalmologists <em>Commissioning Guide: Glaucoma</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">Royal College of Ophthalmologists, 2016</a>], the National Institute for Health and Clinical Excellence (NICE) guideline <em>Glaucoma: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">NICE, 2017</a>] the College of Optometrists guideline <em>Glaucoma (primary open angle) (POAG)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">College of Optometrists, 2018b</a>], and are consistent with the guideline from the Scottish Intercollegiate Guidelines Network (SIGN) <em>Glaucoma referral and safe discharge</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">SIGN, 2015</a>] and with the review article <em>Glaucoma </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">King, 2013</a>]<em>.</em></p><h5>Selective laser trabeculoplasty as a potential first-line treatment</h5><ul><li>A 2019 Health Technology Assessment (HTA) reported the results of a clinical trial to compare health-related quality of life (HRQoL) in newly diagnosed, treatment-naive people with open angle glaucoma or ocular hypertension, initially treated with either topical intraocular pressure (IOP)-lowering medication or primary selective laser trabeculoplasty (SLT), followed by topical medications as required [<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">Gazzard, 2019</a>].<ul><li>356 people were randomized to initial SLT, and 362 people to routine medical treatment only. 91% of people returned the primary outcome questionnaire at 36 months. The EQ-5D-5L score (measuring HRQoL) was not significantly different between the two arms (adjusted mean difference 0.01, 95% confidence interval [CI] –0.01 to 0.03; p = 0.23).</li><li>Over 36 months, the proportion of visits at which intraocular pressure was within the target range was higher in the SLT arm (93.0%, 95% CI 91.9% to 94.0%) than in the topical medicine arm (91.3%, 95% CI 89.9% to 92.5%), with IOP-lowering glaucoma surgery required in 0 and 11 patients, respectively. </li><li>There was a 97% probability of SLT being more cost-effective than topical medicine for the NHS.</li></ul></li><li>The evidence from this HTA was reviewed in an exceptional surveillance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">NICE, 2019b</a>] of the current NICE guideline <em>Glaucoma: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">NICE, 2017</a>].  It was concluded that the current NICE guideline should be updated to reflect the findings of the HTA. However, it was also noted that that there may be a 'considerable resourcing issue in relation to an increase in laser procedures' [<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">NICE, 2019b</a>], which CKS acknowledges may affect ongoing clinical practice.</li></ul><h5>Laser and surgical treatment options in secondary care</h5><ul><li>The information on laser and surgical treatment options available in secondary care is based on expert opinion within the textbook <em>Kanski's Clinical Ophthalmology 8th edition</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">Bowling, 2015</a>].</li></ul><!-- end field 8d0a192f-38a3-4423-92d4-6b87b71fbabf --><!-- end item 10c92530-f2fc-4209-89ed-8df534b69c05 -->","subChapters":[]}]},{"id":"4ad11160-98ab-5be6-8849-3a6d2dde2624","slug":"patient-information-support","fullItemName":"Patient information and support","depth":3,"htmlHeader":"<!-- begin field 697641ee-a5d9-4b4b-8f42-4532706b3f4b --><h3>What information should I give to a person with primary open angle glaucoma or ocular hypertension?</h3><!-- end field 697641ee-a5d9-4b4b-8f42-4532706b3f4b -->","summary":null,"htmlStringContent":"<!-- begin item 611e443d-4371-4fb3-9464-eeea054225ac --><!-- begin field b5ce80f9-4f20-45ff-b4f5-872d80185e38 --><ul><li><strong>Consider offering information such as:</strong><ul><li><strong>The importance of adhering to treatment</strong> to optimize the likelihood of preserving sight.</li><li><strong>If physical problems hinder the correct use of eye drops,</strong> an eye drop dispenser can help position and squeeze the bottle. For example:<ul><li>Xal-ease<sup>®</sup> dispensers for latanoprost.</li><li>Eyot<sup>®</sup> dispensers for travoprost.</li><li>Opticare<sup>®</sup> and Opticare<sup>®</sup> Arthro dispensers are prescribable and are compatible with various eye drop bottles. Opticare<sup>®</sup> dispensers are designed for people whose hands shake, or have difficulty squeezing the bottle. Opticare<sup>®</sup> Arthro dispensers are designed for people with poor hand grip or limited mobility of the hand. </li><li>Autodrop<sup>®</sup> dispensers are compatible with a range of eye drops,</li></ul></li><li><strong>To follow the manufacturers' instructions</strong> carefully on the use and storage of eye preparations.</li><li><strong>To report adverse effects, </strong>if they occur, as other treatment options may be available. <ul><li>Systemic absorption of eye drops, and thus the risk of systemic adverse effects, can be minimized by lacrimal occlusion after instillation of eye drops. Simply closing the eyes for 3 minutes can reduce systemic absorption by about 50% and can be enhanced by pressing a finger on the lacrimal sac for the same time. These measures also prolong the drug–eye contact time. </li><li>Local adverse effects on the periocular skin can be reduced by blotting overflow of the drops with a clean dry tissue after instilling the drops.</li></ul></li><li><strong>That certain benefits may be available</strong> should the person become visually impaired.</li><li><strong>Advice about driving.</strong> Many people with glaucoma are able to continue driving but a person may only drive if their vision fulfils the requirement by the <a href=\"https://www.gov.uk/government/publications/at-a-glance\" data-hyperlink-id=\"e5f7f8e5-8ba1-4414-a0a3-a98e012da503\">Driver and Vehicle Licensing Agency</a> (DVLA). If in doubt, consult the DVLA. In brief:<ul><li>If glaucoma affects just one eye and the other eye has normal field of vision and visual acuity that conforms to the DVLA standards, then group 1 licence holders (ordinary private car) do not need to inform the DVLA and can continue to drive. Rules for group 2 vehicle licence holders (heavy goods vehicles and passenger carrying vehicles) are more stringent and advice should be sought from the DVLA.</li><li>If glaucoma affects both eyes then the person should report their condition to the DVLA who will provide guidance on vision tests required to determine if driving can continue.</li><li>For further information, see the DVLA guidance on <a href=\"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/866655/assessing-fitness-to-drive-a-guide-for-medical-professionals.pdf\" data-hyperlink-id=\"6cca01db-58b0-4caa-b27f-abd8011a51e3\">Assessing fitness to drive – a guide for medical professionals</a>.</li></ul></li><li><strong>Signposting to relevant patient information.</strong> For example, from:<ul><li>The International Glaucoma Association (<a style=\"background-color: #ffffff;\" href=\"http://www.glaucoma-association.com/\" target=\"\" data-hyperlink-id=\"f6c39fab-4db7-40c3-9983-a98e012da51e\">www.glaucoma-association.com</a>).</li><li>The <a href=\"https://www.nhs.uk/conditions/glaucoma/\" data-hyperlink-id=\"278b6d3a-2fb9-4c96-aade-abd800c1e19b\">NHS</a>.</li><li><a href=\"https://patient.info/eye-care/acute-angle-closure-glaucoma/chronic-open-angle-glaucoma\" data-hyperlink-id=\"23f0d0d1-e563-4c3a-9228-abd800c1e1b7\">Patient.info</a>.</li><li>The <a href=\"https://www.rcophth.ac.uk/wp-content/uploads/2017/10/2017_Understanding-Glaucoma.pdf\" data-hyperlink-id=\"7e8f83b0-0d30-4d73-87a4-abd800c1e1fc\">RNIB and Royal College of Ophthalmologists</a>.</li></ul></li></ul></li></ul><!-- end field b5ce80f9-4f20-45ff-b4f5-872d80185e38 --><!-- end item 611e443d-4371-4fb3-9464-eeea054225ac -->","subChapters":[{"id":"e8dbc3ac-e1c7-581c-9b99-ad2ada0b1ceb","slug":"basis-for-recommendation-6e6","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 56d34a4e-3637-4bc5-bdb8-142130146393 --><h4>Basis for recommendation</h4><!-- end field 56d34a4e-3637-4bc5-bdb8-142130146393 -->","summary":null,"htmlStringContent":"<!-- begin item 6e6cf131-6f9e-4f17-975c-2cafc282aae8 --><!-- begin field f063e720-e673-4072-b5fd-9dfe3a82b9e6 --><p>The advice about what information to provide to people with primary open angle glaucoma or ocular hypertension is based on expert opinion in the National Institute of Health and Care Excellence guideline <em>Glaucoma: diagnosis and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">NICE, 2017</a>].</p><!-- end field f063e720-e673-4072-b5fd-9dfe3a82b9e6 --><!-- end item 6e6cf131-6f9e-4f17-975c-2cafc282aae8 -->","subChapters":[]}]},{"id":"8d457845-6f26-5be5-9384-e49c0ef075a3","slug":"allergy-to-eye-drops","fullItemName":"Allergy to eye drops","depth":3,"htmlHeader":"<!-- begin field 51537bbd-17ef-4942-a802-14edc26d76d6 --><h3>How should I recognize and manage allergic reactions to anti-glaucoma eye drops?</h3><!-- end field 51537bbd-17ef-4942-a802-14edc26d76d6 -->","summary":null,"htmlStringContent":"<!-- begin item 4c539bbb-0730-4170-bd66-fa98565d8e2a --><!-- begin field 1be68e6a-22be-47a7-abd3-fb1933229524 --><ul><li><strong>Allergic reactions are usually due to the preservative in the eye drop but can also be due to the active drug.</strong></li><li><strong>Allergic reactions can cause: </strong><ul><li>Eyes and eyelids to itch severely.</li><li>Eyes to become red and injected.</li><li>Eyelids to become red and swollen.</li></ul></li><li><strong>Symptoms and signs become worse after the drops are instilled,</strong> and they resolve when treatment is stopped.</li><li><strong>If allergy to eye drops is suspected:</strong><ul><li><strong>Refer to an ophthalmologist,</strong> or obtain specialist advice about confirming the suspicion of allergy, withdrawing the eye drops, and further treatment. Options that an ophthalmologist may consider include:<ul><li>Replacement with a preservative-free preparation of the same topical drug.</li><li>Replacement with an alternative drug.</li><li>Stopping treatment and monitoring the progress of the condition. This may be more of an option in people with ocular hypertension or suspected glaucoma with low risk of progression to glaucoma.</li></ul></li></ul></li></ul><!-- end field 1be68e6a-22be-47a7-abd3-fb1933229524 --><!-- end item 4c539bbb-0730-4170-bd66-fa98565d8e2a -->","subChapters":[{"id":"bdbff005-e785-53fd-a993-3ffaa3e1f3bf","slug":"basis-for-recommendation-a54","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field d8517582-b82d-4dfb-8761-4a485484ca6e --><h4>Basis for recommendation</h4><!-- end field d8517582-b82d-4dfb-8761-4a485484ca6e -->","summary":null,"htmlStringContent":"<!-- begin item a54cef6d-2e4e-4e1e-931f-754359a77177 --><!-- begin field 6c062eea-086f-4345-8657-d009008ffc80 --><p>The recommendations on how to manage allergic reactions to topical glaucoma medications are based on expert opinion within the National Institute of Health and Care Excellence guideline <em>Glaucoma: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/glaucoma/references/\">NICE, 2017</a>].</p><!-- end field 6c062eea-086f-4345-8657-d009008ffc80 --><!-- end item a54cef6d-2e4e-4e1e-931f-754359a77177 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}